Securities code: 688399 securities abbreviation: Jiangsu Bioperfectus Technologies Co.Ltd(688399) Announcement No.: 2021-041
Jiangsu Bioperfectus Technologies Co.Ltd(688399)
Announcement on voluntary disclosure that the company’s products have obtained EU CE certification
The board of directors and all directors of the company guarantee that there are no false records
Misleading statements or material omissions, and the authenticity, accuracy and completeness of their contents shall be subject to
The law assumes legal responsibility.
Jiangsu Bioperfectus Technologies Co.Ltd(688399) (hereinafter referred to as the “company”)
The rapid detection kit for sars-cov-2 antigen (self-test) was obtained recently
EU CE certificate. After obtaining EU CE certification, the product can be recognized in EU countries and Europe
EU CE certified national sales. The details are as follows:
1、 Relevant certification
Approved subject Jiangsu Bioperfectus Technologies Co.Ltd(688399)
Product name New Coronavirus (SARS-CoV-2) antigen rapid detection kit (self test)
Certificate No.: 1434-ivdd-523 / 2021
The kit is used to detect New Coronavirus’s intended antigen in vivo by nasal swabs, and is suitable for rapid screening of suspected New Coronavirus cases. For home free detection.
Scope of use: EU countries and countries that recognize EU CE certification
Service life: December 23, 2021 to May 27, 2025
2、 Impact on the company
The above products have obtained EU CE certification and have been recognized by EU countries and EU CE
With the certification of national sales access qualification, the company’s overseas sales product categories have been further expanded
The company’s overseas application scenarios of covid-19 testing products are fully expanded, which further improves the company’s international competitiveness and plays a positive role in the company’s overseas sales and international business expansion.
3、 Risk tips
In addition to the above-mentioned products of the company obtaining relevant certification, there are also relevant products of other companies certified for supply to the market, and there are many methods for the detection of covid-19 pneumonia, so the company’s products face the market competition risk of similar products or other detection products; At the same time, the EU CE certification has been obtained this time. The future sales situation depends on the epidemic development and control situation of the above countries and regions, the selection of detection methods, as well as the overseas market promotion of the above products, customer recognition and other factors. The product sales and profit contribution are uncertain, and the company is unable to predict its impact on the company’s future performance. Please pay attention to investment risks.
It is hereby announced.
Jiangsu Bioperfectus Technologies Co.Ltd(688399) board of directors December 27, 2021
